Edwards Lifesciences Corporation (EW)
After hours:
| Previous close | 67.71 |
| Open | 67.46 |
| Bid | 68.04 x 1000 |
| Ask | 68.89 x 1100 |
| Day's range | 67.08 - 68.59 |
| 52-week range | 60.57 - 94.87 |
| Volume | |
| Avg. volume | 4,299,359 |
| Market cap | 41.46B |
| Beta (5Y monthly) | 1.02 |
| PE ratio (TTM) | 29.21 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
CLASP IID ONE-YEAR DATA CONFIRM SAFETY AND EFFICACY OF EDWARDS PASCAL SYSTEM FOR DEGENERATIVE MITRAL REGURGITATION
Edwards Lifesciences Corporation (NYSE: EW) announced one-year results from CLASP IID, the first randomized controlled trial that directly compares two contemporary mitral transcatheter edge-to-edge repair (TEER) therapies, as well as one-year results from the CLASP IID registry. The studies confirm the clinical and quality-of-life benefits of mitral regurgitation (MR) reduction with the PASCAL system in a broad population of patients with degenerative mitral regurgitation (DMR). Results from th
- PR Newswire
TRISCEND II SIX-MONTH DATA FOR FIRST 150 PATIENTS SUCCESSFULLY DEMONSTRATE SAFETY AND EFFICACY OF EDWARDS EVOQUE SYSTEM FOR SEVERE TRICUSPID REGURGITATION
Edwards Lifesciences Corporation (NYSE: EW) today announced successful results from TRISCEND II, a randomized controlled pivotal trial designed to evaluate the safety and effectiveness of the groundbreaking EVOQUE tricuspid valve replacement system with optimal medical therapy (OMT) compared to OMT alone with 2:1 randomization.
- PR Newswire
EDWARDS LIFESCIENCES REPORTS THIRD QUARTER RESULTS
Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Sept. 30, 2023.
